skip to content

Department of Chemical Engineering and Biotechnology

Nature Communications paper for JJ Phillips

The modus operandi in much of medicine is first to determine the key mechanism of a disease process and then to use a drug to inhibit it.

Therefore, on a molecular level, there is often an entity that has an activity that we may wish to turn off. This molecule is termed the ‘drug target’ and a huge amount of effort is made in scientific research and in the pharmaceutical industry to accurately identify these valuable potential weak spots in diseases, such as cancers.

Protein kinases are considered to be the second most important group of drug targets (after G-protein-coupled receptors). The simplest method of drug action against this ubiquitous family of molecules is to bind to a highly conserved pocket, called the ‘active site.’

The key challenge is how to design the drug to specifically bind to just one member of this family. The answer lies in the fact that a protein kinase is not a static structure: it is highly dynamic and occupies (at least) three distinct postures. One of these – the so-called ‘DFG-out’ posture exposes its unique features and this is the form of the protein that must be targeted to design a useful medicine.

Recent work at the CEB Department by JJ Phillips, in collaboration with MedImmune and AstraZeneca, has yielded major insight into the structural dynamics of these kinases. In a paper to Nature Communications (DOI: 10.1038/ncomms8877), they focus on the Fibroblast Growth Factor Receptor 1 (FGFR-1) kinase domain. This protein is heavily implicated in the development of blood vessels in a number of tumour types, including breast, pancreatic, prostate and ovarian cancers. As such, it is a valuable target in cancer research - however, it is highly resistant to adopting this druggable ‘DFG-out’ posture.

This study dissects how the natural, unstimulated activity of the protein is linked to its molecular dynamics in detail resolved at high spatial resolution. This provides a rationale for why FGFR-1 kinase so rarely adopts a druggable state and has proved to be one of the most elusive of high-profile targets in cancer research.

Latest news

Dr Sam Stranks awarded Philip Leverhulme Prize in Physics

18 October 2021

Dr Sam Stranks, who leads our Optoelectronics and Device Spectroscopy Group, has been awarded the 2021 Philip Leverhulme Prize in Physics...

Multi-million-pound centre at the heart of the digital chemistry revolution appoints UK experts to new advisory board

27 September 2021

The Innovation Centre in Digital Molecular Technologies, a multi-million-pound project based at the University of Cambridge, has appointed an External Advisory Board of leading UK experts that will align the centre with both national interests and local priorities in the digital chemistry sector.

Cambridge leads multidisciplinary team in development of a simulator to accelerate the path to net zero flight

27 August 2021

Researchers from CEB will play a key role in the Aviation Impact Accelerator, an international group of experts in aerospace, economics, policy, and climate science, who are developing an interactive evidence-based simulator that explores scenarios for achieving net zero flight.